Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stefanini Benedetta, Bucci Laura, Santi Valentina, Reggidori Nicola, Lani Lorenzo, Granito Alessandro, Pelizzaro Filippo, Cabibbo Giuseppe, Di Marco Mariella, Ghittoni Giorgia, Campani Claudia, Svegliati-Baroni Gianluca, Foschi Francesco Giuseppe, Giannini Edoardo G, Biasini Elisabetta, Saitta Carlo, Magalotti Donatella, Sangiovanni Angelo, Guarino Maria, Gasbarrini Antonio, Rapaccini Gian Ludovico, Masotto Alberto, Sacco Rodolfo, Vidili Gianpaolo, Mega Andrea, Azzaroli Francesco, Nardone Gerardo, Brandi Giovanni, Sabbioni Simone, Vitale Alessandro, Trevisani Franco
Аннотация
METHOD: Between 2008 and 2020, among 774 C-P B patients with aHCC not amenable/responsive to locoregional treatments, 410 underwent sorafenib, 62 MC, and 302 BSC. The propensity score matching method was used to correct the baseline unbalanced prognostic factors.
RESULTS: In the unmatched population, median OS was 9.7 months in patients treated with sorafenib, 8.0 with MC, and 3.9 months with BSC. In sorafenib vs. BSC-matched patients (135 couples), median OS was 7.3 (4.9-9.6) vs. 3.9 (2.6-5.2) months (p<0.001). ECOG-Performance Status, tumor size, macrovascular invasion, AFP, treatment-naive, and sorafenib were independent predictors of survival. In MC vs. BSC-matched patients (40 couples), median OS was 9.0 (0.2-17.8) vs.3.0 (2.2-3.8) months (p<0.001). Median OS did not differ (p = 0.283) in sorafenib vs. MC-matched patients (55 couples).
CONCLUSION: C-P B patients with aHCC undergoing BSC have poor survival. Both Sorafenib and MC treatment improve their prognosis.